The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Speakers' Bureau - Bristol-Myers Squibb
United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.
 
Ahmad A. Tarhini
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Genentech/Roche; Incyte; Merck; Newlink Genetics; Novartis; OncoSec
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); GreenPeptide (Inst); Incyte (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Prometheus (Inst); Prometheus (Inst)
 
Sandra J. Lee
Employment - NantWorks (I)
Stock and Other Ownership Interests - NantWorks (I)
Consulting or Advisory Role - Roche/Genentech
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Stock and Other Ownership Interests - Apricity Health
Consulting or Advisory Role - Aduro Biotech; Amgen; Bayer; Bristol-Myers Squibb; Celldex; EMD Serono; Genentech/Roche; Incyte; Incyte; Incyte; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi; Verastem
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Uma N. M. Rao
No Relationships to Disclose
 
Gary Irvin Cohen
Stock and Other Ownership Interests - Abbvie; Celgene; Nymox
 
Omid Hamid
Honoraria - Amgen; Array BioPharma; Bristol-Myers Squibb; Genentech/Roche; Novartis; Sanofi/Regeneron
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Roche
Speakers' Bureau - Amgen; Array BioPharma; Bristol-Myers Squibb; Genentech; Novartis; Sanofi/Regeneron
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); NextCure (Inst); Novartis (Inst); Parker Institute for Cancer Immunotherapy (Inst); Pfizer (Inst); Polynoma (Inst); Regeneron (Inst); Roche (Inst)
 
Laura Fulper Hutchins
Research Funding - Abbott/AbbVie (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Polynoma (Inst)
 
Jeffrey Alan Sosman
Honoraria - Bristol-Myers Squibb; Genentech; MSD Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech; MSD Oncology
 
Harriet M. Kluger
Consulting or Advisory Role - Biodesix; Celldex; Corvus Pharmaceuticals; Genentech/Roche; Immunocore; Iovance Biotherapeutics; Merck; Nektar; Pfizer
Research Funding - Apexigen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Apexigen
 
Vernon K. Sondak
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Castle Biosciences; EMD Serono; Genentech/Roche; Illumina; Merck/Schering Plough; Novartis; OncoSec; Pfizer; Polynoma; Sun Pharma
 
Henry B. Koon
No Relationships to Disclose
 
Donald P. Lawrence
No Relationships to Disclose
 
Kari Lynn Kendra
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Novartis (Inst)
 
David R. Minor
Stock and Other Ownership Interests - Bristol-Myers Squibb (I)
Consulting or Advisory Role - Atreca; theravance
Speakers' Bureau - Bristol-Myers Squibb; Merck/Schering Plough
 
Carrie B. Lee
Consulting or Advisory Role - Delcath Systems
Travel, Accommodations, Expenses - Novartis
 
Mark R. Albertini
Research Funding - Apeiron Biologics (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst)
 
Lawrence E. Flaherty
Consulting or Advisory Role - HUYA Bioscience International; Merck/Schering Plough
Travel, Accommodations, Expenses - Merck/Schering Plough
 
Teresa M. Petrella
Honoraria - Abbvie (I); Astellas Pharma (I); Bayer (I); Bristol-Myers Squibb; Genzyme; Incyte; Janssen (I); Merck; Novartis; Sanofi (I)
Consulting or Advisory Role - Abbvie (I); Astellas Pharma (I); Bayer (I); Bristol-Myers Squibb; Genzyme; InCyte; Janssen (I); Merck; Novartis
Research Funding - Novartis Canada Pharmaceuticals Inc; Roche Canada
 
John M. Kirkwood
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Immunocore; Merck; Novartis; Roche
Research Funding - Immunocore (Inst); Merck (Inst); Prometheus (Inst)